https://bionxt.com/xphyto-therapeutics-receives-german-cannabis-licence-for-scientific-cultivation-and-extraction/ 2021-02-08T13:54:00+00:00 monthly 0.2 https://bionxt.com/xphyto-therapeutics-commences-trading-on-the-cse/ 2021-02-08T13:54:00+00:00 monthly 0.2 https://bionxt.com/xphyto-therapeutics-commences-trading-on-the-frankfurt-stock-exchange/ 2021-02-08T13:54:00+00:00 monthly 0.2 https://bionxt.com/xphyto-therapeutics-enters-cannabis-research-and-development-agreement-with-the-technical-university-of-munich/ 2021-02-08T13:54:00+00:00 monthly 0.2 https://bionxt.com/xphyto-therapeutics-to-acquire-german-narcotics-company/ 2021-02-08T13:54:00+00:00 monthly 0.2 https://bionxt.com/xphyto-therapeutics-closes-acquisition-of-vektor-pharma-tf-gmbh/ 2021-02-08T13:54:00+00:00 monthly 0.2 https://bionxt.com/xphyto-therapeutics-signs-exclusive-cannabis-agreement-with-elite-bavarian-brewing-beverage-institute/ 2021-02-08T13:54:00+00:00 monthly 0.2 https://bionxt.com/engaging-global-cannabis-expert-for-german-operations/ 2021-02-08T14:03:53+00:00 monthly 0.2 https://bionxt.com/xphyto-signs-term-sheet-for-german-cannabis-distribution/ 2021-02-08T14:05:33+00:00 monthly 0.2 https://bionxt.com/xphyto-therapeutics-oral-and-transdermal-cannabis-delivery-and-dosage-systems/ 2021-07-27T16:29:16+00:00 monthly 0.2 https://bionxt.com/xphyto-therapeutics-pharmaceutical-grade-cannabis-extraction-lab/ 2021-02-08T14:12:17+00:00 monthly 0.2 https://bionxt.com/xphyto-therapeutics-developing-epilepsy-treatment-with-oral-thin-film-delivery-system/ 2021-07-27T16:29:16+00:00 monthly 0.2 https://bionxt.com/three-year-strategic-supply-import-and-distribution-agreement-with-pharmacielo-ltd-signed/ 2021-02-08T14:16:12+00:00 monthly 0.2 https://bionxt.com/exclusive-strategic-partnership-commenced-with-elite-bavarian-brewing-beverage-institute-weihenstephan-tum/ 2021-02-08T14:17:52+00:00 monthly 0.2 https://bionxt.com/xphyto-initiates-infectious-disease-programs/ 2021-07-27T16:27:44+00:00 monthly 0.2 https://bionxt.com/update-on-xphytos-epilepsy-treatment-program/ 2021-07-27T16:29:16+00:00 monthly 0.2 https://bionxt.com/covid-19-test-and-development-programs-update/ 2021-07-27T16:27:44+00:00 monthly 0.2 https://bionxt.com/exclusive-advisory-agreement-for-covid-19-and-host-cell-interactions-signed/ 2021-02-08T14:40:10+00:00 monthly 0.2 https://bionxt.com/covid-19-screening-test-oral-thin-film-biosensor-products-and-identification-platform/ 2021-07-27T16:27:44+00:00 monthly 0.2 https://bionxt.com/infectious-disease-oral-dissolvable-biosensor-development/ 2021-07-27T16:27:44+00:00 monthly 0.2 https://bionxt.com/exclusive-agreement-with-oettinger-brewery-for-cannabis-infused-beverages-signed/ 2021-07-27T16:28:25+00:00 monthly 0.2 https://bionxt.com/parkinsons-generic-transdermal-drug-delivery-system/ 2021-07-27T16:29:16+00:00 monthly 0.2 https://bionxt.com/diagnostic-partner-3a-receives-bmbf-grant-for-infectious-disease-screening-tests/ 2021-07-27T16:27:44+00:00 monthly 0.2 https://bionxt.com/infectious-disease-oral-screening-test-advancement/ 2021-07-27T16:27:44+00:00 monthly 0.2 https://bionxt.com/infectious-disease-oral-biosensor-function-confirmed/ 2021-07-27T16:27:43+00:00 monthly 0.2 https://bionxt.com/covid-19-rapid-screening-test-prototype-validation/ 2021-07-27T16:27:43+00:00 monthly 0.2 https://bionxt.com/xphyto-provides-update-on-covid-19-rapid-test/ 2021-07-27T16:27:43+00:00 monthly 0.2 https://bionxt.com/xphyto-announces-otcqb-venture-market-listing/ 2021-02-08T21:45:40+00:00 monthly 0.2 https://bionxt.com/xphyto-provides-update-on-parkinsons-transdermal-patch/ 2021-07-27T16:29:16+00:00 monthly 0.2 https://bionxt.com/update-on-covid-19-rapid-test-commercialization/ 2021-07-27T16:27:43+00:00 monthly 0.2 https://bionxt.com/update-on-oral-thin-film-drug-delivery-programs/ 2021-07-27T16:29:16+00:00 monthly 0.2 https://bionxt.com/update-on-contract-drug-delivery-programs/ 2021-07-27T16:29:16+00:00 monthly 0.2 https://bionxt.com/xphyto-announces-rt-pcr-test-for-point-of-care-covid-19-detection/ 2021-07-27T16:27:43+00:00 monthly 0.2 https://bionxt.com/xphyto-engages-german-partner-for-development-of-psilocybin-api-production/ 2021-07-27T16:28:25+00:00 monthly 0.2 https://bionxt.com/xphyto-appoints-european-healthcare-executive-to-board-of-directors/ 2021-02-08T22:08:05+00:00 monthly 0.2 https://bionxt.com/exclusive-psychedelic-drug-development-agreement-secured/ 2021-07-27T16:28:25+00:00 monthly 0.2 https://bionxt.com/xphyto-completes-successful-sars-cov-2-rt-pcr-diagnostic-test-kit-validation/ 2021-07-27T16:27:43+00:00 monthly 0.2 https://bionxt.com/xphyto-announces-business-strategy-and-milestones-for-2021/ 2021-02-08T22:15:30+00:00 monthly 0.2 https://bionxt.com/xphyto-announces-drug-formulation-strategy-and-2021-milestones/ 2021-07-27T16:29:16+00:00 monthly 0.2 https://bionxt.com/xphyto-announces-psychedelic-pharmaceutical-production-agreement/ 2021-07-27T16:28:25+00:00 monthly 0.2 https://bionxt.com/xphyto-adds-mescaline-production-to-psychedelic-medicine-programs/ 2021-07-27T16:28:25+00:00 monthly 0.3 https://bionxt.com/xphyto-european-ce-ivd-application-for-25-minute-covid-19-rt-pcr-test/ 2021-07-27T16:27:43+00:00 monthly 0.2 https://bionxt.com/xphyto-builds-commercial-team-to-launch-25-minute-covid-19-rt-pcr-test/ 2021-07-27T16:27:43+00:00 monthly 0.2 https://bionxt.com/xphyto-places-first-order-for-25-minute-covid-19-rt-pcr-tests/ 2021-07-27T16:26:41+00:00 monthly 0.2 https://bionxt.com/xphyto-provides-updated-comments-on-promotional-and-marketing-activity/ 2021-03-04T17:41:30+00:00 monthly 0.2 https://bionxt.com/xphyto-completes-corporate-rebranding-and-launches-new-website/ 2021-03-04T17:41:03+00:00 monthly 0.2 https://bionxt.com/xphyto-partner-receives-iso-certification-for-25-minute-covid-19-rt-pcr-test/ 2021-07-27T16:26:30+00:00 monthly 0.2 https://bionxt.com/xphyto-announces-european-approval-for-25-minute-covid-19-pcr-test/ 2021-07-27T16:26:22+00:00 monthly 0.2 https://bionxt.com/xphyto-adds-top-level-executive-talent-to-its-global-operations/ 2021-04-20T07:19:51+00:00 monthly 0.2 https://bionxt.com/xphyto-signs-german-distribution-storage-and-logistics-agreement-for-25-minute-covid-19-pcr-test/ 2021-07-27T16:26:13+00:00 monthly 0.2 https://bionxt.com/xphyto-pursues-market-access-in-israel-for-its-covid-19-pcr-rapid-test/ 2021-07-27T16:26:04+00:00 monthly 0.2 https://bionxt.com/xphyto-establishes-proof-of-concept-station-for-point-of-care-25-minutes-pcr-test-in-germany/ 2021-07-27T16:25:47+00:00 monthly 0.2 https://bionxt.com/xphyto-provides-update-on-drug-formulation-and-development-business/ 2021-07-27T16:25:54+00:00 monthly 0.2 https://bionxt.com/xphyto-rapid-point-of-care-covid-19-pcr-test-offered-for-sale-in-germany/ 2021-05-19T20:11:55+00:00 monthly 0.2 https://bionxt.com/xphyto-provides-progress-report-on-mescaline-program-for-psychedelic-therapies/ 2021-07-27T16:25:32+00:00 monthly 0.2 https://bionxt.com/xphyto-supplies-10-test-centers-in-berlin-with-25-minute-covid-19-pcr-test/ 2021-07-27T16:25:11+00:00 monthly 0.2 https://bionxt.com/xphyto-signs-transformative-acquisition-agreement-with-3a-diagnostics-to-enter-hi-tech-biosensor-market-and-expand-its-diagnostic-product-portfolio/ 2021-07-27T16:25:17+00:00 monthly 0.2 https://bionxt.com/xphytos-acquisition-target-3a-diagnostics-reports-breakthrough-identification-of-covid-19-biosensor-candidates/ 2021-07-28T06:26:40+00:00 monthly 0.2 https://bionxt.com/xphyto-launches-first-commercial-biosensor-for-oral-disease/ 2021-08-29T18:31:41+00:00 monthly 0.2 https://bionxt.com/xphyto-reports-successful-market-launch-and-growing-demand-for-its-25-minute-covid-19-pcr-test-covid-id-lab/ 2021-09-08T07:00:20+00:00 monthly 0.2 https://bionxt.com/xphyto-reports-development-update-for-its-drug-delivery-business/ 2021-10-12T06:47:15+00:00 monthly 0.2 https://bionxt.com/xphyto-announces-managing-director-appointment-financing-and-3a-diagnostics-development/ 2021-11-03T07:16:36+00:00 monthly 0.2 https://bionxt.com/xphyto-therapeutics-closes-private-placements-for-gross-proceeds-of-70000000/ 2021-11-29T08:05:03+00:00 monthly 0.2 https://bionxt.com/xphyto-completes-strategic-acquisition-of-3a-diagnostics-gmbh/ 2021-12-06T07:45:46+00:00 monthly 0.2 https://bionxt.com/xphyto-epilepsy-clinical-trial-planned-in-2022-with-its-proprietary-fast-dissolving-cbd-oral-strips/ 2021-12-15T08:11:29+00:00 monthly 0.2 https://bionxt.com/xphyto-announces-new-director-of-business-development-and-head-of-diagnostic-research/ 2022-01-10T08:09:04+00:00 monthly 0.2 https://bionxt.com/xphyto-signs-distribution-agreement-for-czech-republic-rollout-planned-for-hungary-slovakia-ukraine-and-russia/ 2022-01-13T07:53:40+00:00 monthly 0.2 https://bionxt.com/xphyto-announces-head-of-sales-europe/ 2022-01-17T07:55:30+00:00 monthly 0.2 https://bionxt.com/xphyto-provides-update-on-integration-of-3a-diagnostics-gmbh/ 2022-01-25T07:56:41+00:00 monthly 0.2 https://bionxt.com/xphyto-executes-covid-id-lab-sales-contracts-with-test-clinics-and-pharmacies-in-germany-as-part-of-multi-product-rollout-strategy/ 2022-02-01T08:11:39+00:00 monthly 0.2 https://bionxt.com/xphyto-reports-on-its-three-primary-business-divisions/ 2022-02-08T08:02:15+00:00 monthly 0.2 https://bionxt.com/xphyto-provides-progress-update-on-psychedelic-medicine-programs-and-novel-compounds-milestone/ 2022-02-22T08:07:42+00:00 monthly 0.2 https://bionxt.com/xphyto-reports-market-and-product-developments-on-platform-based-rotigotine-transdermal-patch-for-parkinsons-disease/ 2022-04-04T06:44:34+00:00 monthly 0.2 https://bionxt.com/xphyto-biosensors-market-and-product-developments-on-platform-based-oral-dissolvable-biosensors-for-oral-health-and-infectious-disease/ 2022-04-12T09:40:30+00:00 monthly 0.2 https://bionxt.com/xphyto-reports-product-developments-on-platform-based-rotigotine-transdermal-patch-for-parkinsons-disease/ 2022-05-09T07:01:20+00:00 monthly 0.2 https://bionxt.com/xphyto-adds-pharmaceutical-manufacturing-expert-dr-florian-a-sahr-to-its-european-team/ 2022-06-08T08:24:41+00:00 monthly 0.2 https://bionxt.com/prof-dr-raimar-loebenberg-receives-leadership-award-from-the-canadian-society-for-pharmaceutical-sciences/ 2022-06-27T08:01:06+00:00 monthly 0.2 https://bionxt.com/xphyto-pursues-potential-application-of-its-oral-dissolvable-biosensor-inflammation-test-for-buprenorphine-related-dental-disease/ 2022-07-18T06:49:56+00:00 monthly 0.2 https://bionxt.com/xphyto-files-patent-application-for-library-of-novel-psychedelic-compounds/ 2022-10-05T07:30:41+00:00 monthly 0.2 https://bionxt.com/xphyto-signs-letter-of-intent-for-us-manufacturing-and-strategic-business-opportunities/ 2022-10-05T07:33:27+00:00 monthly 0.2 https://bionxt.com/xphyto-completes-rotigotine-transdermal-patch-optimization-and-comparative-skin-absorption-study/ 2022-10-18T07:25:13+00:00 monthly 0.2 https://bionxt.com/xphyto-reports-excellent-rotigotine-in-vitro-ex-vivo-results-for-parkinsons-disease-treatment/ 2022-10-18T07:22:21+00:00 monthly 0.2 https://bionxt.com/bionxt-reports-update-on-commercialization-of-rotigotine-patch-for-treatment-of-parkinsons-disease/ 2023-02-16T14:08:53+00:00 monthly 0.2 https://bionxt.com/bionxt-signs-clinical-study-agreement-and-commences-manufacture-of-clinical-samples-for-study-of-transdermal-rotigotine-patch-for-parkinsons-disease/ 2023-03-01T09:20:24+00:00 monthly 0.2 https://bionxt.com/bionxt-solutions-acquires-novel-precision-drug-coating-and-delivery-technology/ 2023-03-07T10:32:09+00:00 monthly 0.2 https://bionxt.com/bionxt-acquires-commercial-coating-and-cutting-equipment-to-build-out-european-commercial-manufacturing-capacity/ 2023-12-14T09:22:03+00:00 monthly 0.2 https://bionxt.com/bionxt-secures-contract-to-develop-and-manufacture-odf-product-for-international-pharmaceutical-company/ 2023-12-14T09:20:43+00:00 monthly 0.2 https://bionxt.com/bionxt-successfully-completes-pilot-study-for-contract-development-customer/ 2023-12-14T09:19:35+00:00 monthly 0.2 https://bionxt.com/bionxt-receives-approval-for-european-clinical-studyof-transdermal-rotigotine-patch-for-parkinsons-disease/ 2023-12-14T09:17:11+00:00 monthly 0.2 https://bionxt.com/bionxt-signs-loi-for-acquisition-of-ip-and-co-development-of-odf-drug-reformulation-for-neurodegenerative-disease/ 2023-12-14T09:17:51+00:00 monthly 0.2 https://bionxt.com/bionxt-signs-definitive-agreement-for-100-acquisition-of-ip-and-co-development-of-cladribine-odf-drug-reformulation-for-the-treatment-of-multiple-sclerosis/ 2023-12-14T09:13:46+00:00 monthly 0.2 https://bionxt.com/bionxt-reports-on-new-cladrabine-odf-product-development-and-commercialization-program/ 2023-12-14T09:12:13+00:00 monthly 0.2 https://bionxt.com/bionxt-accelerates-cladribine-odf-clinical-and-commercialization-strategy-for-multiple-sclerosis-treament/ 2023-12-14T09:09:21+00:00 monthly 0.2 https://bionxt.com/bionxt-receives-delivery-of-premium-commercial-coating-and-cutting-equipment-for-commercial-manufacturing-of-drug-delivery-products/ 2023-12-14T09:04:53+00:00 monthly 0.2 https://bionxt.com/bionxt-reports-successful-results-from-odf-cladribine-toxicity-study/ 2024-02-08T10:11:02+00:00 monthly 0.2 https://bionxt.com/bionxt-reports-completion-of-odf-cladribine-pk-study/ 2024-03-11T09:36:12+00:00 monthly 0.2 https://bionxt.com/bionxt-reports-successful-results-from-odf-cladribine-pk-study/ 2024-03-13T08:54:51+00:00 monthly 0.2 https://bionxt.com/bionxt-reports-commercialization-of-odf-cladribine-product-for-ms-next-steps/ 2024-03-18T10:58:55+00:00 monthly 0.2 https://bionxt.com/terry-lynch-joins-bionxt-as-capital-markets-advisor/ 2024-11-14T15:55:17+00:00 monthly 0.2 https://bionxt.com/bionxt-announces-national-level-patent-filings-for-sublingual-anticancer-drugs-for-the-treatment-of-autoimmune-neurodegenerative-diseases/ 2024-11-14T15:52:56+00:00 monthly 0.2 https://bionxt.com/bionxt-announces-enhanced-sublingual-product-development-pipeline-with-innovative-solutions-for-autoimmune-diseases-and-longevity/ 2024-12-02T09:04:58+00:00 monthly 0.2 https://bionxt.com/bionxt-solutions-announces-development-of-sublingual-thin-film-for-semaglutide/ 2024-12-02T10:20:21+00:00 monthly 0.2 https://bionxt.com/bionxt-solutions-reports-progress-on-bnt23001-development-for-multiple-sclerosis-treatment/ 2024-12-09T08:44:53+00:00 monthly 0.2 https://bionxt.com/bionxt-solutions-expands-patent-protection-for-drug-delivery-innovations-backed-by-positive-iprp/ 2024-12-19T09:14:03+00:00 monthly 0.2 https://bionxt.com/bionxt-accelerates-rd-with-move-to-gen-plus-laboratory-in-munich-germany-expanding-drug-delivery-research-capabilities/ 2025-01-21T10:15:41+00:00 monthly 0.2 https://bionxt.com/bionxt-solutions-prepares-for-human-bioequivalence-study-for-multiple-sclerosis-ms/ 2025-04-23T07:37:57+00:00 monthly 0.2 https://bionxt.com/bionxt-solutions-reports-expanded-patent-protection-from-the-eurasian-patent-organization/ 2025-05-05T07:08:09+00:00 monthly 0.2 https://bionxt.com/bionxt-reports-expanded-research-development-and-commercialization-capability-with-centralized-munich-laboratory/ 2025-05-13T08:01:03+00:00 monthly 0.2 https://bionxt.com/bionxt-solutions-reports-formal-notice-from-the-european-patent-office-of-intention-to-grant-patent/ 2025-05-23T07:22:49+00:00 monthly 0.2 https://bionxt.com/bionxt-launches-feasibility-study-for-semaglutide-oral-thin-film-as-alternative-to-injection-tablets/ 2025-06-25T11:08:43+00:00 monthly 0.2 https://bionxt.com/api-delivery-initiates-next-phase-for-bionxts-sublingual-cladribine-multiple-sclerosis-program/ 2025-07-07T09:46:53+00:00 monthly 0.2 https://bionxt.com/bionxt-solutions-introduces-targeted-chemotherapy-drug-delivery-platform-for-precision-oncology/ 2025-07-09T06:05:17+00:00 monthly 0.2 https://bionxt.com/bionxt-delivers-positive-results-in-patented-cladribine-sublingual-thin-film-program-and-completes-successful-formulation/ 2025-07-23T07:16:14+00:00 monthly 0.2 https://bionxt.com/bionxt-solutions-reports-pending-patent-grants-in-europe-and-eurasia-strengthening-ip-protection-for-proprietary-sublingual-cladribine-based-ms-treatment/ 2025-08-05T17:48:08+00:00 monthly 0.2 https://bionxt.com/bionxt-fast-tracks-u-s-patent-for-ms-drug-and-secures-broad-platform-ip-covering-autoimmune-neurology-pipeline/ 2025-08-20T09:20:22+00:00 monthly 0.2 https://bionxt.com/semaglutide-api-delivery-enables-start-of-lab-scale-odf-development-at-bionxt/ 2025-09-02T10:26:04+00:00 monthly 0.2 https://bionxt.com/bionxt-solutions-completes-up-listing-to-the-otcqb-market/ 2025-09-05T07:41:25+00:00 monthly 0.2 https://bionxt.com/bionxt-advances-semaglutide-oral-dissolvable-film-odf-program-with-successful-proof-of-concept-and-prototype-development/ 2025-09-16T06:03:37+00:00 monthly 0.2 https://bionxt.com/bionxt-reports-sublingual-cladribine-multiple-sclerosis-drug-milestones-including-large-animal-study-for-validation-and-dosing-optimization/ 2025-09-29T09:14:01+00:00 monthly 0.2 https://bionxt.com/bionxt-reports-update-on-targeted-chemotherapy-drug-delivery-platform/ 2025-10-02T08:07:45+00:00 monthly 0.2 https://bionxt.com/bionxt-completes-fast-track-us-track-one-patent-filing-for-sublingual-delivery-of-cladribine-for-the-treatment-of-multiple-sclerosis/ 2025-10-13T07:15:41+00:00 monthly 0.2 https://bionxt.com/bionxt-launches-15-day-sublingual-cladribine-dosing-optimization-study-in-preparation-for-human-bioequivalence-study/ 2025-11-04T21:32:29+00:00 monthly 0.2 https://bionxt.com/bionxt-reports-readiness-to-grant-patent-notification-from-the-eurasian-patent-organization/ 2025-11-04T21:31:30+00:00 monthly 0.2 https://bionxt.com/bionxt-reports-intention-to-grant-patent-notification-from-the-european-patent-office-for-its-oral-cladribine-sublingual-thin-film-as-the-multiple-sclerosis-market-shifts-toward-patient-friendly-t/ 2025-11-04T13:10:05+00:00 monthly 0.2 https://bionxt.com/bionxt-secures-final-patent-grant-from-the-eurasian-patent-organization-for-sublingual-cladribine-platform/ 2025-11-20T08:40:53+00:00 monthly 0.2 https://bionxt.com/bionxt-advances-melt-in-your-mouth-cladribine-formulation-to-improve-treatment-for-ms-patients-with-dysphagia/ 2025-12-09T08:24:07+00:00 monthly 0.2 https://bionxt.com/over-40-of-adults-struggle-to-swallow-pills-bionxt-targets-a-global-adherence-problem-with-rapid-dissolving-thin-film-melt-in-your-mouth-therapies/ 2025-12-17T08:35:10+00:00 monthly 0.2 https://bionxt.com/bionxt-reports-successful-final-in-vivo-dosing-study-results-supporting-superior-bioavailability-of-cladribine-sublingual-odf/ 2026-01-21T06:54:33+00:00 monthly 0.2 https://bionxt.com/bionxt-reports-final-preclinical-results-demonstrating-approximately-40-higher-cladribine-delivery-for-the-treatment-multiple-sclerosis-ms/ 2026-01-21T08:14:23+00:00 monthly 0.2 https://bionxt.com/bionxt-accelerates-odf-for-multiple-sclerosis-toward-human-clinical-study-with-40-bioavailability-improvement-and-myasthenia-gravis-expansion/ 2026-01-26T08:25:25+00:00 monthly 0.2 https://bionxt.com/bionxt-secures-innovative-chaperone-technology-to-enhance-oral-thin-film-drug-delivery/ 2026-02-05T08:29:31+00:00 monthly 0.2 https://bionxt.com/bionxt-receives-milestone-epo-decision-to-grant-european-patent-for-sublingual-cladribine-drug-delivery-technology-for-multiple-sclerosis/ 2026-03-31T10:35:33+00:00 monthly 0.2 https://bionxt.com/bionxt-signs-strategic-agreement-for-eurasian-commercialization-following-cladribine-odf-patent-grant-in-eurasia-and-europe/ 2026-03-31T10:35:42+00:00 monthly 0.2 https://bionxt.com/bionxt-enters-commercialization-phase-with-global-patent-protection-and-u-s-fast-track-strategy-for-sublingual-drug-delivery-platform/ 2026-03-31T10:35:53+00:00 monthly 0.2 https://bionxt.com/bionxt-advances-semaglutide-as-first-application-of-broad-glp-1-odf-platform-strategy/ 2026-03-31T10:36:01+00:00 monthly 0.2 https://bionxt.com/bionxt-secures-unitary-european-patent-for-sublingual-cladribine-odf-platform-across-18-countries/ 2026-04-07T07:10:52+00:00 monthly 0.2 https://bionxt.com/bionxt-initiates-gmp-manufacturing-of-clinical-grade-sublingual-cladribine-film-targeting-multiple-sclerosis-ms/ 2026-04-14T09:27:23+00:00 monthly 0.2 https://bionxt.com/bionxt-applies-advanced-drug-delivery-strategy-and-psychedelic-compound-library-to-emerging-therapeutics-market-amid-accelerating-global-momentum/ 2026-04-28T07:10:29+00:00 monthly 0.2 https://bionxt.com/bionxt-advances-semaglutide-odf-program-into-active-pharmaceutical-development/ 2026-05-19T07:26:06+00:00 monthly 0.2 https://bionxt.com/bionxt-engages-business-development-licensing-advisors-for-commercialization-of-patented-sublingual-cladribine-odf/ 2026-06-15T07:55:40+00:00 monthly 0.2 https://bionxt.com/bionxt-treibt-das-glp-1-programm-fur-sublinguales-semaglutid-odf-voran-nachste-phase-der-verabreichungsentwicklung-lauft/ 2026-07-06T14:55:17+00:00 monthly 0.2 https://bionxt.com/bionxt-advances-cladribine-clinical-program-with-completion-of-the-investigational-medicinal-product-dossier-impd-ahead-of-human-clinical-studies/ 2026-08-19T17:48:49+00:00 monthly 0.2 https://bionxt.com/bionxt-advances-sublingual-everolimus-odf-for-organ-transplant-rejection-with-initiation-of-large-animal-pharmacokinetic-study/ 2026-09-08T08:18:57+00:00 monthly 0.2